MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients
Open Access
- 30 December 2015
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 10 (1) , 1-8
Abstract
Rheumatoid Arthritis is a chronic disease leading to decreased quality of life with a rather variable response rate to Disease Modifying Anti Rheumatic Drugs. Methotrexate (MTX) is the gold standard therapy in Rheumatoid Arthritis. The Multidrug resistance Related Protein and Multi Drug Resistance protein 1, also called P-glycoprotein-170 transporters can alter the intracellular concentration of different drugs. Methotrexate is an MRP1 substrate and thus the functional activity of MRP1 might have a clinical impact on the efficiency of the Methotrexate-therapy in Rheumatoid Arthritis. We have compared the functional Multidrug Activity Factors (MAF) of the MDR1 and MRP1 transporters of Peripheral Blood Leukocytes of 59 Rheumatoid Arthritis patients with various response rate to MTX-therapy (MTX-responder, MTX-resistant and MTX-intolerant RA-groups) and 47 non-RA controls in six different leukocyte subpopulations (neutrophil leukocytes, monocytes, lymphocytes, CD4+, CD8+ and CD19+ cells). There was a decreased MAF of RA patients compared to non- Rheumatoid Arthritis patients and healthy controls in the leukocyte subpopulations. There was a significant difference between the MAF values of the MTX-responder and MTX intolerant groups. But we have not found significant differences between the MAF values of the MTX-responder and MTX-resistant Rheumatoid Arthritis -groups. Our results suggest that MDR1 and MRP1 functional activity does not seem to affect the response rate to MTX-therapy of Rheumatoid Arthritis-patients, but it might be useful in predicting MTX-side effects. We have demonstrated the decreased functional MDR-activity on almost 60 Rheumatoid Arthritis patients, which can be interpreted as a sign of the immune-suppressive effect of the MTX-treatment.Keywords
This publication has 24 references indexed in Scilit:
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trialArthritis & Rheumatism, 2008
- Quality-of-Life Assessment in Rheumatoid ArthritisPharmacoEconomics, 2008
- Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedsideNature Clinical Practice Rheumatology, 2007
- Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drugAnnals of the Rheumatic Diseases, 2006
- Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Therapeutic Strategies for Rheumatoid ArthritisNew England Journal of Medicine, 2004
- P-glycoprotein in autoimmune diseasesAutoimmunity Reviews, 2004
- Contribution of patient related differences to multidrug resistance in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- EXPRESSION OF THE MULTDORUG RESISTANCE GLYCOPROTEIN 170 IN THE PERIPHERAL BLOOD LYMPHOCYTES OF RHEUMATOID ARTHRITIS PATIENTS. THE PERCENTAGE OF LYMPHOCYTES EXPRESSING GLYCOPROTEIN 170 IS INCREASED IN PATIENTS TREATED WITH PREDNISOLONERheumatology, 1996
- P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vincristineBiochimica et Biophysica Acta (BBA) - General Subjects, 1995